I ran across three blurbs last week demonstrating how hard it is to improve diabetes outcomes.   In my recent blog “Beyond A1C” I reviewed the evidence that control of blood pressure, lipids and glucose, in that order, had been demonstrated to reduce the vascular complications of diabetes.   I have ... Read More »

So, Dr. Macaulay Onuigbo continued his detective work at Mayo Clinic to find out the reasons why in his cohort constituted of mostly severe and old CKD  patients who got better, when stopped ACE-Is or ARBs, while the  minority of them who did not get better, died soon later. he found many interesting scientific ... Read More »

A few years later the Angiotensin Receptor Blockers ((ARBs) were released into the market and advertised as more specific Angiotensin II blockers without the side effects of cough. Not even one single comparative head to head clinical trial trial was done regarding effectiveness or safety of renal protection between ACE-I ... Read More »

The worldwide epidemic of type 2 diabetes has the potential to overwhelm the health care system.    The vast majority of costs associated with type 2 diabetes results from its micro- and macrovascular complications that are potentially preventable by aggressive treatment of hyperglycemia and associated ... Read More »

 Certainly we should be aware and study the effects of persistent chemicals on health.  However, we also need to be sure that the results are correctly stated especially in the lay press. ... Read More »